Lapatinib Teva

Lapatinib, the active ingredient in Lapatinib Teva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric cancer in adult patients.

GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lapatinib is a targeted oral therapy used in HER2‑driven cancers. It is indicated for the following conditions: - HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with chemotherapy. - HER2‑positive metastatic gastric cancer: used with capecitabine to delay disease progression. - HER2‑positive early‑stage breast cancer (adjuvant setting): administered after surgery to reduce recurrence risk.

Lapatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools, may require hydration. - Rash: skin redness, often on trunk or extremities. - Nausea: upset stomach, sometimes with vomiting. - Fatigue: persistent tiredness affecting daily activities. - Hand‑foot syndrome: redness or swelling of palms and soles. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Liver toxicity: elevated transaminases, jaundice. - Cardiac dysfunction: decreased left‑ventricular ejection fraction. - Interstitial lung disease: breathing difficulty, cough. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - QT interval prolongation: risk of arrhythmia. - Severe diarrhea leading to dehydration.

Before initiating Lapatinib, clinicians should consider several safety measures. - Liver monitoring: check hepatic enzymes regularly. - Cardiac assessment: evaluate baseline ejection fraction and repeat as needed. - Skin surveillance: watch for severe rash or mucosal lesions. - Diarrhea management: treat early to prevent dehydration. - Drug interactions: avoid strong CYP3A4 inhibitors or inducers without dose adjustment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lapatinib interacts with several medicines that affect its metabolism or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lapatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids containing aluminum or magnesium: can lower absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Digoxin: possible increase in serum levels, check cardiac function. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for muscle toxicity. - Proton pump inhibitors: may modestly affect drug levels, observe clinical response.